Review
Nature Reviews Immunology 6, 343-357 (May 2006) | doi:10.1038/nri1837
Corrected online: 18 April 2006
Focus on: Translational immunology
Potent antibody therapeutics by design
Paul J. Carter1 About the author
Abstract
Antibodies constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The generation of potent antibody therapeutics, which I review here, is an iterative design process that involves the generation and optimization of antibodies to improve their clinical potential.
- View At a Glance
Author affiliations
-
Department of Antibody Technologies, Seattle Genetics Incorporated, 21823 30th Drive South East, Bothell, Washington 98021, USA.
Email: pcarter@seagen.com
Published online 7 April 2006
* Table 1 in this article has been amended. A new PDF has replaced the previous version.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
The rollercoaster ride to anti-cancer antibodiesNature Biotechnology Research News (01 May 2003)
Full-length antibodies on displayNature Biotechnology News and Views (01 May 2007)
See all 4 matches for News And ViewsRESEARCH
Engineered antibody fragments and the rise of single domainsNature Biotechnology Research (01 Sep 2005)
See all 10 matches for Research
